Impairment of bone health in pediatric patients with hemolytic anemia

PLoS One. 2014 Oct 9;9(10):e108400. doi: 10.1371/journal.pone.0108400. eCollection 2014.

Abstract

Introduction: Sickle cell anemia and thalassemia result in impaired bone health in both adults and youths. Children with other types of chronic hemolytic anemia may also display impaired bone health.

Study design: To assess bone health in pediatric patients with chronic hemolytic anemia, a cross-sectional study was conducted involving 45 patients with different forms of hemolytic anemia (i.e., 17 homozygous sickle cell disease and 14 hereditary spherocytosis patients). Biochemical, radiographic and anamnestic parameters of bone health were assessed.

Results: Vitamin D deficiency with 25 OH-vitamin D serum levels below 20 ng/ml was a common finding (80.5%) in this cohort. Bone pain was present in 31% of patients. Analysis of RANKL, osteoprotegerin (OPG) and osteocalcin levels indicated an alteration in bone modeling with significantly elevated RANKL/OPG ratios (control: 0.08+0.07; patients: 0.26+0.2, P = 0.0007). Osteocalcin levels were found to be lower in patients compared with healthy controls (68.5+39.0 ng/ml vs. 118.0+36.6 ng/ml, P = 0.0001). Multiple stepwise regression analysis revealed a significant (P<0.025) influence of LDH (partial r2 = 0.29), diagnosis of hemolytic anemia (partial r2 = 0.05) and age (partial r2 = 0.03) on osteocalcin levels. Patients with homozygous sickle cell anemia were more frequently and more severely affected by impaired bone health than patients with hereditary spherocytosis.

Conclusion: Bone health is impaired in pediatric patients with hemolytic anemia. In addition to endocrine alterations, an imbalance in the RANKL/OPG system and low levels of osteocalcin may contribute to this impairment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anemia, Hemolytic / blood*
  • Anemia, Hemolytic / physiopathology*
  • Bone Density / physiology
  • Bone and Bones / physiopathology*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Osteocalcin / blood
  • Osteoprotegerin / blood
  • RANK Ligand / blood

Substances

  • Osteoprotegerin
  • RANK Ligand
  • Osteocalcin

Grants and funding

JB was supported by the Essen University Hospital Foundation ‘Stiftung Universitätsmedizin’. MS and CG were supported by an IFORES stipend from the ‘Faculty of Medicine, University of Duisburg-Essen’. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.